Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.40 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.36 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354537 | 0.87 | ITGAV (0.41) | ITGAVITGB6ITGB3CXCR4ITGB8 | |
| SCHEMBL21715687 | 0.84 | ITGAV (0.39) | ITGAVITGB6ITGB3CXCR4ITGB5 | |
| SCHEMBL279379 | 0.82 | CXCR4 (0.42) | ITGAVITGB6ITGB3CXCR4ITGA2B | |
| SCHEMBL4762028 | 0.80 | ITGB3 (0.50) | ITGAVITGB6ITGB3ITGA2BITGB5 | |
| SCHEMBL19544248 | 0.77 | CXCR4 (0.39) | ITGAVITGB6ITGB3CXCR4ITGA2B | |
| SCHEMBL325378 | 0.75 | CXCR4 (0.39) | ITGAVITGB6ITGB3CXCR4ITGA2B | |
| SCHEMBL4530325 | 0.74 | ITGAV (0.43) | ITGAVITGB6ITGB3CXCR4ITGA2B | |
| SCHEMBL7435472 | 0.74 | ITGAV (0.54) | ITGAVITGB6ITGB3 | |
| SCHEMBL7797597 | 0.73 | ITGAV (0.51) | ITGAVITGB6ITGB3CXCR4ITGA2B | |
| SCHEMBL28337166 | 0.73 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | BAX, BAD, BCL2 | ITGAV 4843/4885ITGB6 4504/4885ITGB3 4646/4885 |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | BAX, BAD, BCL2 | ITGAV 4843/4885ITGB6 4504/4885ITGB3 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.